GPX4 and B-cell chronic lymphocytic leukemia: As proof of principle, we evaluated the combination of ibrutinib and the GPX4 inhibitor RSL3 in a preclinical TCL1 mouse model of CLL.20 The combination therapy proved to be significantly more effective than monotherapy with either ibrutinib or RSL3, supporting the potential clinical relevance of ferroptosis induction as a therapeutic strategy in CLL.